Clinical & Experimental Metastasis最新文献_第2页

The role of host response to chemotherapy: resistance, metastasis and clinical implications. 宿主对化疗反应的作用:耐药、转移和临床意义。

IF 4.2 3区医学

Clinical & Experimental Metastasis Pub Date : 2024-08-01 Epub Date: 2023-11-24 DOI: 10.1007/s10585-023-10243-5

Abhilash Deo, Jonathan P Sleeman, Yuval Shaked

{"title":"The role of host response to chemotherapy: resistance, metastasis and clinical implications.","authors":"Abhilash Deo, Jonathan P Sleeman, Yuval Shaked","doi":"10.1007/s10585-023-10243-5","DOIUrl":"10.1007/s10585-023-10243-5","url":null,"abstract":"Chemotherapy remains the primary treatment for most metastatic cancers. However, the response to chemotherapy and targeted agents is often transient, and concurrent development of resistance is the primary impediment to effective cancer therapy. Strategies to overcome resistance to treatment have focused on cancer cell intrinsic factors and the tumor microenvironment (TME). Recent evidence indicates that systemic chemotherapy has a significant impact on the host that either facilitates tumor growth, allowing metastatic spread, or renders treatment ineffective. These host responses include the release of bone marrow-derived cells, activation of stromal cells in the TME, and induction of different molecular effectors. Here, we provide an overview of chemotherapy-induced systemic host responses that support tumor aggressiveness and metastasis, and which contribute to therapy resistance. Studying host responses to chemotherapy provides a solid basis for the development of adjuvant strategies to improve treatment outcomes and delay resistance to chemotherapy. This review discusses the emerging field of host response to cancer therapy, and its preclinical and potential clinical implications, explaining how under certain circumstances, these host effects contribute to metastasis and resistance to chemotherapy.","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138298565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Editorial: Cancer metastasis through the lymphovascular system: molecular mechanisms of cancer metastasis. 癌症通过淋巴管系统转移：癌症转移的分子机制。

IF 4.2 3区医学

Clinical & Experimental Metastasis Pub Date : 2024-08-01 Epub Date: 2024-02-28 DOI: 10.1007/s10585-024-10272-8

Stanley P Leong, S David Nathanson, Jonathan S Zager

引用次数: 0

Cancer metastasis through the lymphatic versus blood vessels. 癌症通过淋巴和血管转移。

IF 4.2 3区医学

Clinical & Experimental Metastasis Pub Date : 2024-08-01 Epub Date: 2024-06-28 DOI: 10.1007/s10585-024-10288-0

Stanley P Leong, Marlys H Witte

引用次数: 0

Antigen presenting cells in cancer immunity and mediation of immune checkpoint blockade. 癌症免疫中的抗原递呈细胞和免疫检查点阻断的中介作用。

IF 4.2 3区医学

Clinical & Experimental Metastasis Pub Date : 2024-08-01 Epub Date: 2024-01-23 DOI: 10.1007/s10585-023-10257-z

Cassia Wang, Lee Chen, Doris Fu, Wendi Liu, Anusha Puri, Manolis Kellis, Jiekun Yang

{"title":"Antigen presenting cells in cancer immunity and mediation of immune checkpoint blockade.","authors":"Cassia Wang, Lee Chen, Doris Fu, Wendi Liu, Anusha Puri, Manolis Kellis, Jiekun Yang","doi":"10.1007/s10585-023-10257-z","DOIUrl":"10.1007/s10585-023-10257-z","url":null,"abstract":"Antigen-presenting cells (APCs) are pivotal mediators of immune responses. Their role has increasingly been spotlighted in the realm of cancer immunology, particularly as our understanding of immunotherapy continues to evolve and improve. There is growing evidence that these cells play a non-trivial role in cancer immunity and have roles dependent on surface markers, growth factors, transcription factors, and their surrounding environment. The main dendritic cell (DC) subsets found in cancer are conventional DCs (cDC1 and cDC2), monocyte-derived DCs (moDC), plasmacytoid DCs (pDC), and mature and regulatory DCs (mregDC). The notable subsets of monocytes and macrophages include classical and non-classical monocytes, macrophages, which demonstrate a continuum from a pro-inflammatory (M1) phenotype to an anti-inflammatory (M2) phenotype, and tumor-associated macrophages (TAMs). Despite their classification in the same cell type, each subset may take on an immune-activating or immunosuppressive phenotype, shaped by factors in the tumor microenvironment (TME). In this review, we introduce the role of DCs, monocytes, and macrophages and recent studies investigating them in the cancer immunity context. Additionally, we review how certain characteristics such as abundance, surface markers, and indirect or direct signaling pathways of DCs and macrophages may influence tumor response to immune checkpoint blockade (ICB) therapy. We also highlight existing knowledge gaps regarding the precise contributions of different myeloid cell subsets in influencing the response to ICB therapy. These findings provide a summary of our current understanding of myeloid cells in mediating cancer immunity and ICB and offer insight into alternative or combination therapies that may enhance the success of ICB in cancers.","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11374820/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139519048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Revealing the concealed: A tribute to Donald L. Morton, MD. 揭示隐秘：向唐纳德-L-莫顿医学博士致敬。

IF 4.2 3区医学

Clinical & Experimental Metastasis Pub Date : 2024-08-01 Epub Date: 2023-07-31 DOI: 10.1007/s10585-023-10223-9

S David Nathanson, Ian Wood

{"title":"Revealing the concealed: A tribute to Donald L. Morton, MD.","authors":"S David Nathanson, Ian Wood","doi":"10.1007/s10585-023-10223-9","DOIUrl":"10.1007/s10585-023-10223-9","url":null,"abstract":"Donald L. Morton, MD, epitomized one of America's dream scenarios: a person evolving from the humblest of origins to become an international celebrity in his profession, leading the world in the discipline of surgical oncology. His pioneering accomplishments in various roles have been well documented. Scientists, clinicians, students, and patients benefited from his contributions to the management of malignant diseases, particularly melanoma. His many attributes in pursuing the goal to cure malignant diseases are well known. Browsing the scientific literature reveals an almost unmatched publication record and continuous National Institutes of Health funding. He revealed dozens of original concealed ideas, not least of which is the tumor-draining regional lymph node, now called the sentinel lymph node (SLN). When others gave up on the original promise of immunotherapy, he saw the future, the clinical promise which has lately materialized in the control of previously untreatable malignancies. He regarded the fellowship-training of more than 100 surgical oncologists as one of his biggest achievements. In this article, we celebrate the human side of a man with creative courage and far-reaching insight.","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9901083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Associations amongst genes, molecules, cells, and organs in breast cancer metastasis. 乳腺癌转移中基因、分子、细胞和器官之间的关联。

IF 4.2 3区医学

Clinical & Experimental Metastasis Pub Date : 2024-08-01 Epub Date: 2023-09-09 DOI: 10.1007/s10585-023-10230-w

S David Nathanson, Lothar C Dieterich, Xiang H-F Zhang, Dhananjay A Chitale, Lajos Pusztai, Emma Reynaud, Yi-Hsuan Wu, Alejandro Ríos-Hoyo

引用次数: 0

Lymphatic trafficking of immune cells and insights for cancer metastasis. 免疫细胞的淋巴迁移和癌症转移的启示。

IF 4.2 3区医学

Clinical & Experimental Metastasis Pub Date : 2024-08-01 Epub Date: 2023-08-22 DOI: 10.1007/s10585-023-10229-3

David G Jackson

{"title":"Lymphatic trafficking of immune cells and insights for cancer metastasis.","authors":"David G Jackson","doi":"10.1007/s10585-023-10229-3","DOIUrl":"10.1007/s10585-023-10229-3","url":null,"abstract":"Most cancers and in particular carcinomas metastasise via the lymphatics to draining lymph nodes from where they can potentially achieve systemic dissemination by invasion of high endothelial blood venules (HEVs) in the paracortex [1, 2]. Currently however, the mechanisms by which tumours invade and migrate within the lymphatics are incompletely understood, although it seems likely they exploit at least some of the normal physiological mechanisms used by immune cells to access lymphatic capillaries and traffic to draining lymph nodes in the course of immune surveillance, immune modulation and the resolution of inflammation [3, 4]. Typically these include directional guidance via chemotaxis, haptotaxis and durotaxis, adhesion to the vessel surface via receptors including integrins, and junctional re-modelling by MMPs (Matrix MetalloProteinases) and ADAMs (A Disintegrin And Metalloproteinases) [5-7]. This short review focusses on a newly emerging mechanism for lymphatic entry that involves the large polysaccharide hyaluronan (HA) and its key lymphatic and immune cell receptors respectively LYVE-1 (Lymphatic Vessel Endothelial receptor) and CD44, and outlines recent work which indicates this axis may also be used by some tumours to aid nodal metastasis.","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11374813/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10039749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical applications of circulating tumor cells in patients with solid tumors. 循环肿瘤细胞在实体瘤患者中的临床应用。

IF 4.2 3区医学

Clinical & Experimental Metastasis Pub Date : 2024-08-01 Epub Date: 2024-01-28 DOI: 10.1007/s10585-024-10267-5

Daniel J Smit, Svenja Schneegans, Klaus Pantel

引用次数: 0

Oncolytic intralesional therapy for metastatic melanoma. 针对转移性黑色素瘤的肿瘤溶解性鞘内疗法。

IF 4.2 3区医学

Clinical & Experimental Metastasis Pub Date : 2024-08-01 Epub Date: 2023-08-09 DOI: 10.1007/s10585-023-10228-4

Danielle K DePalo, Matthew C Perez, Anne Huibers, Roger Olofsson Bagge, Jonathan S Zager

引用次数: 0

How much do we know about the metastatic process? 我们对转移过程了解多少？

IF 4.2 3区医学

Clinical & Experimental Metastasis Pub Date : 2024-08-01 Epub Date: 2024-03-23 DOI: 10.1007/s10585-023-10248-0

Carolina Rodriguez-Tirado, Maria Soledad Sosa

{"title":"How much do we know about the metastatic process?","authors":"Carolina Rodriguez-Tirado, Maria Soledad Sosa","doi":"10.1007/s10585-023-10248-0","DOIUrl":"10.1007/s10585-023-10248-0","url":null,"abstract":"Cancer cells can leave their primary sites and travel through the circulation to distant sites, where they lodge as disseminated cancer cells (DCCs), even during the early and asymptomatic stages of tumor progression. In experimental models and clinical samples, DCCs can be detected in a non-proliferative state, defined as cellular dormancy. This state can persist for extended periods until DCCs reawaken, usually in response to niche-derived reactivation signals. Therefore, their clinical detection in sites like lymph nodes and bone marrow is linked to poor survival. Current cancer therapy designs are based on the biology of the primary tumor and do not target the biology of the dormant DCC population and thus fail to eradicate the initial or subsequent waves of metastasis. In this brief review, we discuss the current methods for detecting DCCs and highlight new strategies that aim to target DCCs that constitute minimal residual disease to reduce or prevent metastasis formation. Furthermore, we present current evidence on the relevance of DCCs derived from early stages of tumor progression in metastatic disease and describe the animal models available for their study. We also discuss our current understanding of the dissemination mechanisms utilized by genetically less- and more-advanced cancer cells, which include the functional analysis of intermediate or hybrid states of epithelial-mesenchymal transition (EMT). Finally, we raise some intriguing questions regarding the clinical impact of studying the crosstalk between evolutionary waves of DCCs and the initiation of metastatic disease.","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11374507/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140193513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0